​Lexaria Bioscience Announces Further Advancement of Edibles Nicotine Testing: Delivery Measured Within Minutes

Spotlight News  |

Lexaria Bioscience Corp.  (LXRP);  (LXX:CNX), a drug delivery platform innovator, announces that it has successfully delivered nicotine in an edible form into blood plasma just minutes after dosing in an animal in vivo study. Lexaria's DehydraTECH™ technology delivered nicotine at each of the 2, 4, 6, 8 and 10-minute intervals post-dosing, with 90.2% greater delivery than the concentration-matched control formulation by the 10-minute mark (95% CI; p=0.044), and significantly greater absorption levels than the control formulation at all subsequent time points in the study.

Speed of onset is a key attribute for oral drug administration, and it is of particular importance for the consideration of non-inhalation nicotine delivery formats.

Lexaria contracted a third-party laboratory to perform the study which focused on detailed analysis of absorption over a 60-minute period, with particular emphasis on the first 15-minutes after dosing (n=40; two groups of 20 rats per group; nicotine polacrilex dosage at 10mg/kg). This study is in follow-up to in vivo study results previously announced on April 17, 2018 which utilized a smaller animal population over a 6-hour period.

Key highlights are as follows:

  • Peak Level: 79% improvement in peak blood levels (maximum concentration or "Cmax") at 394 ng/mL using Lexaria's DehydraTECHTMtechnology vs. 220 ng/mL with the control (95% CI; p=0.0257);
  • Total Quantity: 94% improvement in total quantity of nicotine delivered (area under the curve or "AUC") to the blood during the 60-minute course of the study, at 266 hr•ng/mL versus 137 hr•ng/mL (95% CI; p=0.0086);
  • Rapidity: Lexaria's technology delivered nicotine into the blood stream by the first time interval of blood sampling at the 2-minute mark. On average, Lexaria's technology delivered 203 ng/mL to the blood in aggregate of the 2, 4, 6, 8, 10, 12 and 15-minute time points, compared to only 120 ng/mL in aggregate over the same period by the control, an improvement of 70% (95% CI; p=0.0004).

A significant amount of data has yet to be received and analyzed from this study, including brain absorption data. The blood plasma data from this nicotine study is considered statistically significant and corroborates and confirms the validity of the results previously announced on April 17, 2018.

DehydraTECH™ Formulation (nicotine polacrilex 10 mg/Kg)

Control Formulation (nicotine polacrilex 10 mg/Kg)

% Improvement

pValue

Average Nicotine Blood Level 0-15 min (ng/mL)

203

120

70

0.0004

Peak Nicotine Blood Level 0-60 min (ng/mL)

394

220

79

0.0257

Total Nicotine Absorption (i.e., AUC) 0-60 min (hr∙ng/mL)

266

137

94

0.0086

According to the CDC, global deaths from smoking are currently 6 million per year and expected to reach 8 million yearly by 2030. For every fatality from smoking 30 more people live with serious smoking-related illness. (www.cdc.gov/tobacco)

"Lexaria's DehydraTECH™ breakthrough technology is demonstrating significant effectiveness in delivering nicotine into the bloodstream much more rapidly than we thought possible, and at levels approaching two times more effective than controls," said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. "If we can develop viable ingestible alternatives to cigarette smoking we could help hundreds of millions of people avoid many of the disease states associated with smoking and I cannot imagine a more rewarding destiny bestowed upon Lexaria Bioscience Corp."

Lexaria's in vitro laboratory, in vivo animal and human clinical absorption studies have consistently shown faster delivery and more effective delivery of substances such as nicotine and cannabinoids. Lexaria continues to focus on advancing both its R&D and commercialization initiatives with its DehydraTECHTM technology platform.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
LXRP Lexaria Bioscience Corp. 1.09 0.03 2.83 55,125
LXX:CNX Lexaria Bioscience Corp 1.43 0.03 2.14 42,243

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
XOM

     

Level Headed at World Crypto Con - Steve Beauregard

Bloq.com CRO Steve Beauregard joins Jack Brewer at World Crypto Con.

Emerging Growth

Invictus MD Strategies Corp

Invictus MD Strategies Corp is focused on two main verticals within the Canadian cannabis sector under the Access to Cannabis for Medical Purposes Regulations having investment in Acreage Pharms Ltd.,…